Investigating digital follow-up monitoring for long-term stable blood conditions

A multi-centre investigation of the use of a digital follow-up pathway utilising the Ascelus app for monitoring long-term blood conditions, incorporating patient, carer, and healthcare professionals co-design and evaluation, clinical validation, and safety investigations

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN15125462

Enrollment

2440

Registered

2023-09-11

Start date

2022-09-01

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic lymphocytic leukemia (CLL), haemochromatosis, iron-deficient anaemia, myelodysplastic syndromes (MDS), monoclonal gammopathy of uncertain significance (MGUS), smouldering/asymptomatic myeloma, sickle cell disease (SCD), Waldenstrom’s macroglobulinemia Not Applicable

Interventions

This study has five arms: Arm 1 – Patient and carer co-design, collecting qualitative data on patient satisfaction and empowerment on follow-up pathways, via focus groups and individual interviews A

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion for Arm 1: Patient/carer with a relevant condition at a participating Trust Inclusion for Arm 2: Healthcare professionals or other healthcare professional in relevant discipline Inclusion for Arm 3: Healthcare professional in a relevant discipline or with a relevant special interest Inclusion for Arm 4: 1. Diagnosis with a relevant stable condition 2. 16 years of age or older at the start date for data collection 3. Under the care of a participating Trust Inclusion criteria for Arm 5: 1. Diagnosis with a relevant stable condition 2. 16 years of age or older at the study start 3. Under the care of a participating Trust 4. Able to access and use the Ascelus platform

Exclusion criteria

Exclusion criteria: Exclusion for Arms 1 - 4: None Exclusion for Arm 5: Presence of co-morbidities that would require regular review in the clinic

Design outcomes

Primary

Measure	Time frame
Patient satisfaction, empowerment, and quality of life on a new digital follow-up pathway, using EQ5D and PAM-13 questionnaires at baseline, 6, and 12 months following enrolment, alongside focus groups and interviews at 6 months following enrolment	—

Secondary

Measure	Time frame
1. Safety of the digital follow-up pathway, using progression and adverse incident data taken from clinical records. This will be measured retrospectively for the cohort in the 6 months prior to enrolment, and at 6 and 12 months following enrolment 2. Cost-effectiveness of the digital follow-up pathway when compared to face-to-face and telephone appointments, using a detailed Healthcare Resource Utilisation survey taken at baseline, 6, and 12 months following enrolment 3. Healthcare professionals' satisfaction with the digital follow-up pathway, using clinician focus groups prior to app implementation and at 6 months following patient enrolment	—

Measure

Time frame

1. Safety of the digital follow-up pathway, using progression and adverse incident data taken from clinical records. This will be measured retrospectively for the cohort in the 6 months prior to enrolment, and at 6 and 12 months following enrolment 2. Cost-effectiveness of the digital follow-up pathway when compared to face-to-face and telephone appointments, using a detailed Healthcare Resource Utilisation survey taken at baseline, 6, and 12 months following enrolment 3. Healthcare professionals' satisfaction with the digital follow-up pathway, using clinician focus groups prior to app implementation and at 6 months following patient enrolment

—

Countries

England, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026